Klet S, Marković B, Janić T, Stojković M, Ćirić J, Beleslin BN, et al. Steroid-resistant Graves’orbitopathy–therapeutic options. Med Glas Spec Boln za Boles štitaste žlezde Boles Metab. 2023;28:78–90.

Google Scholar 

Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658. https://doi.org/10.1155/2017/1297658.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu C, Lai CL, Yang CM, Liao KC, Kao CS, Chang TC, et al. The relationship between obesity-related factors and Graves’ orbitopathy: a pilot study. Medicine. 2022;58:1748 https://doi.org/10.3390/medicina58121748.

Article  Google Scholar 

Gupta P, Kaur N, Goyal A, Aggarwal A. Atypical asymmetric presentation of severe Graves’ orbitopathy. Cureus. 2023;15:e45907. https://doi.org/10.7759/cureus.45907.

Article  PubMed  PubMed Central  Google Scholar 

Buldygina YV, Terekhova GM, Strafun LS, Savosko II, Lysova ZG, Shlyakhtych SL. Assessing the efficacy of various treatment regimens for patients with endocrine ophthalmopathy associated with Graves’ disease. J Ophthalmol. 2022;96:311–28.

Brammen L, Riss P, Lukas J, Gessl A, Dunkler D, Li S, et al. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves’ ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial. Trials. 2018;19:495. https://doi.org/10.1186/s13063-018-2876-0.

Article  PubMed  PubMed Central  Google Scholar 

Kumata K, Nagata K, Matsushita M, Kuwamoto S, Kato M, Murakami I, et al. Thyrotropin Receptor Antibody (TRAb)-IgM levels are markedly higher than TRAb-IgG levels in Graves’ disease patients and controls, and TRAb-IgM production is related to Epstein-Barr virus reactivation. Viral Immunol. 2016;29:459–63. https://doi.org/10.1089/vim.2016.0043.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwon H, Kim WG, Jang EK, Kim M, Park S, Jeon MJ, et al. Usefulness of measuring thyroid stimulating antibody at the time of antithyroid drug withdrawal for predicting relapse of Graves disease. Endocrinol Metab. 2016;31:300–10. https://doi.org/10.3803/EnM.2016.31.2.300.

Article  CAS  Google Scholar 

Menon LP, Naqvi S, Maradana J, Edem D. Recurrent Graves’ disease following near-total thyroidectomy: a case report and literature review. Cureus. 2024;16:e52260. https://doi.org/10.7759/cureus.52260.

Article  PubMed  PubMed Central  Google Scholar 

Park J, Kim J, Kim SS, Choi HY. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe Graves’ orbitopathy. Front Endocrinol. 2023;14:1153312. https://doi.org/10.3389/fendo.2023.1153312.

Article  Google Scholar 

Ujianto M, Sari F, Rakhman MF. Unveiling modern strategies for diagnosing and treating grave orbitopathy. J Klin dan Ris Kesehat. 2024;3:89–106.

Google Scholar 

Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020;16:104–16. https://doi.org/10.1038/s41574-019-0305-4.

Article  CAS  PubMed  Google Scholar 

Walasik-Szemplińska D, Kamiński G, Sudoł-Szopińska I. Impact of radioiodine treatment on doppler flow parameters in the central retinal artery and ophthalmic artery in patients with hyperthyroidism. J Ultrasound Med. 2021;40:305–18. https://doi.org/10.1002/jum.15401.

Article  PubMed  Google Scholar 

Byeon HJ, Chae MK, Ko J, Lee EJ, Kikkawa DO, Jang SY, et al. The role of adipsin, complement factor D, in the pathogenesis of Graves’ orbitopathy. Invest Ophthalmol Vis Sci. 2023;64:13 https://doi.org/10.1167/iovs.64.11.13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nowak M, Siemińska L, Karpe J, Marek B, Kos-Kudła B, Kajdaniuk D. Serum concentrations of HGF and IL-8 in patients with active Graves’ orbitopathy before and after methylprednisolone therapy. J Endocrinol Investig. 2016;39:63–72. https://doi.org/10.1007/s40618-015-0322-7.

Article  CAS  Google Scholar 

Soler ZM, Platt MP, Leung MK, Mong S, Metson R. Sinonasal abnormalities in patients with Graves’ orbitopathy. Laryngoscope. 2011;121:656–60. https://doi.org/10.1002/lary.21392.

Article  PubMed  Google Scholar 

Ponto KA, Pitz S, Mann WJ, Weber MM, Pfeiffer N, Kahaly GJ. Vorgehen bei endokriner Orbitopathie. Evidenzbasierte Empfehlungen [Management of Graves’ orbitopathy: evidence-based recommendations]. Dtsch Med Wochenschr. 2009;134:2521–4. https://doi.org/10.1055/s-0029-1243057.

Article  CAS  PubMed  Google Scholar 

Devarbhavi P, Maiti A, Sinha A, Basu A, Chakraborty S, Dey L, et al. Rituximab therapy in steroid resistant thyroid associated ophthalmopathy. Case Rep Int. 2017;6:1–4. https://doi.org/10.5348/crint-2017-36-CR-5.

Article  Google Scholar 

Sisti E, Menconi F, Leo M, Profilo MA, Mautone T, Mazzi B, et al. Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Investig. 2015;38:661–8. https://doi.org/10.1007/s40618-015-0241-7.

Article  CAS  Google Scholar 

Eckstein A, Schittkowski M, Esser J. Surgical treatment of Graves’ ophthalmopathy. Best Pr Res Clin Endocrinol Metab. 2012;26:339–58. https://doi.org/10.1016/j.beem.2011.11.002.

Article  Google Scholar 

Eing F, Cruz AA. Surgical treatment of globe subluxation in the active phase of the myogenic type of Graves orbitopathy: case reports. Arq Bras Oftalmol. 2012;75:131–3. https://doi.org/10.1590/s0004-27492012000200012.

Article  PubMed  Google Scholar 

Salvi M, Campi I. Medical Treatment of Graves’ Orbitopathy. Horm Metab Res. 2015;47:779–88. https://doi.org/10.1055/s-0035-1554721.

Article  CAS  PubMed  Google Scholar 

Shen WC, Lee CH, Loh EW, Hsieh AT, Chen L, Tam KW. Efficacy and safety of rituximab for the treatment of Graves’ orbitopathy: a meta-analysis of randomized controlled trials. Pharmacotherapy. 2018;38:503–10. https://doi.org/10.1002/phar.2111.

Article  CAS  PubMed  Google Scholar 

Oakman G, Ong C. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis with overlap IgA nephropathy: a case report. Case Rep Nephrol Dial. 2024;14:36–41. https://doi.org/10.1159/000536618.

Article  PubMed  PubMed Central  Google Scholar 

Duarte AF, Xavier NF, Sales Sanz M, Cruz AAV. Efficiency and safety of tocilizumab for the treatment of thyroid eye disease: a systematic review. Ophthalmic Plast Reconstr Surg. 2024;40:367–73. https://doi.org/10.1097/IOP.0000000000002573.

Article  PubMed  Google Scholar 

Sánchez-Bilbao L, Martínez-López D, Revenga M, López-Vázquez Á, Valls-Pascual E, Atienza-Mateo B, et al. Anti-IL-6 Receptor tocilizumab in refractory Graves’ orbitopathy: national multicenter observational study of 48 patients. J Clin Med. 2020;9:2816 https://doi.org/10.3390/jcm9092816.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bartalena L. Role of teprotumumab in the treatment of active moderate-to-severe Graves’ orbitopathy. Eur Thyroid J. 2022;11:e220185 https://doi.org/10.1530/ETJ-22-0185.

Article  PubMed  PubMed Central  Google Scholar 

Lin F, Yao Q, Yu B, Deng Z, Qiu J, He R. The efficacy and safety of teprotumumab in thyroid eye disease: evidence from randomized controlled trials. Int J Clin Pr. 2023;2023:6638089. https://doi.org/10.1155/2023/6638089.

Article  CAS  Google Scholar 

Xavier NF, Lucena DT, Cruz AAV. Monoclonal antibodies for the treatment of graves orbitopathy: precision medicine?. Ophthalmic Plast Reconstr Surg. 2023;39:307–15. https://doi.org/10.1097/IOP.0000000000002315.

Article  PubMed  Google Scholar 

Fatani WA, Hamdan DM, Taher NO, Alsharef JF, Aldubi RM, Alwagdani AM, et al. Monoclonal antibodies for the treatment of Graves’ ophthalmopathy: a systematic review and meta-analysis. Saudi J Ophthalmol. 2023;37:137–48. https://doi.org/10.4103/sjopt.sjopt_176_22.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71 https://doi.org/10.1136/bmj.n71.

Article  PubMed  PubMed Central  Google Scholar